Trial Search Results

Non-Invasive Diagnosis of Pediatric Pulmonary Invasive Mold Infections

This study will establish a non-invasive diagnostic approach and evaluate clinical outcomes for children at high-risk for pulmonary invasive mold infection (PIMI).

Stanford is currently accepting patients for this trial.

Lead Sponsor:

Duke University

Collaborator: National Institute of Allergy and Infectious Diseases (NIAID)

Stanford Investigator(s):

Intervention(s):

  • Diagnostic Test: Non-Invasive Testing for PIMI

Eligibility


Inclusion Criteria:

   - Males or females age > 120 days and < 22 years at any participating site

   - Have at least one of the following conditions associated with a known high incidence
   of IMI: hematopoietic stem cell transplantation (HSCT), aplastic anemia, or
   hematologic malignancy

   - New (last 96 hours) radiographic evidence of at least one of the following: at least
   one nodular lesion greater than or equal to 5 mm in size, a cavitary lesion, a lesion
   with a halo sign, a lesion with a reverse halo sign, or a lesion with an air crescent
   sign

   - Prolonged neutropenia (absolute neutrophil count < 500 cells/µl for a period of ≥ 5
   consecutive days) in 30 days prior to qualifying chest MRI or CT scan date OR
   currently receiving systemic therapy for acute or chronic graft-versus-host disease
   (GVHD) on the date of the qualifying chest MRI or CT scan

   - Subject consent or parental/guardian permission (informed consent) and if appropriate,
   child assent

Exclusion Criteria:

   - Weight <3 kg, so as to not exceed 3 ml/kg in a single blood draw

   - Previous inclusion in this study

Ages Eligible for Study

120 Days - 21 Years

Genders Eligible for Study

All

Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Angelee Vaid
510-940-3376
Recruiting